Biogen (NASDAQ:BIIB) Price Target Raised to $177.00

Biogen (NASDAQ:BIIB) had its price target lifted by Piper Sandler from $157.00 to $177.00 in a report released on Monday, Marketbeat.com reports. Piper Sandler currently has a neutral rating on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the company. Wedbush increased their price target on Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a report on Monday. HC Wainwright raised their target price on shares of Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research note on Monday. Stifel Nicolaus lifted their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a report on Friday, February 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Biogen in a research report on Tuesday, January 13th. Thirteen analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $206.54.

Biogen Price Performance

Shares of BIIB opened at $191.20 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The firm has a 50-day simple moving average of $177.65 and a 200-day simple moving average of $158.12. The company has a market capitalization of $28.06 billion, a price-to-earnings ratio of 21.70, a price-to-earnings-growth ratio of 1.50 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the business earned $3.44 EPS. The firm’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities research analysts anticipate that Biogen will post 15.83 earnings per share for the current year.

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Privium Fund Management B.V. acquired a new stake in Biogen in the second quarter valued at $2,666,000. Nordea Investment Management AB grew its holdings in Biogen by 5.7% during the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock worth $15,810,000 after acquiring an additional 6,811 shares in the last quarter. Convergence Investment Partners LLC bought a new stake in shares of Biogen in the 3rd quarter worth about $1,342,000. Pitcairn Co. acquired a new stake in shares of Biogen in the 2nd quarter valued at about $936,000. Finally, Fluent Financial LLC bought a new position in shares of Biogen during the third quarter worth about $3,578,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat FY‑2026 guidance — Biogen reported Q4 results that topped EPS and revenue expectations and provided FY‑2026 EPS guidance (15.25–16.25) that reassured investors about earnings power. This is a primary driver of recent price strength. Why Biogen Is Up After Earnings
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms raised targets and reiterated buys after the results (examples: Mizuho, Goldman Sachs, Canaccord, Citigroup and others), supporting further upside sentiment. Mizuho Raises Price Target
• Positive Sentiment: Regulatory progress for Leqembi (lecanemab) — The BLA for a subcutaneous formulation of Leqembi received priority review, which could expand commercial reach and margins if approved. That helped sentiment around Biogen’s Alzheimer’s growth runway. Leqembi Subcutaneous Priority Review
• Neutral Sentiment: Board leadership change — Caroline Dorsa is retiring as Board Chair; Dr. Maria C. Freire was elected Chair effective immediately. Governance continuity reduces uncertainty but is unlikely to be a major near‑term price mover. Board Chair Transition
• Neutral Sentiment: Pipeline diversification updates — Advances in lupus and SMA programs improve long‑term optionality but will take time to drive revenue; these were noted by coverage but are not immediate catalysts. Pipeline Advances
• Neutral Sentiment: Short‑interest data appears inconsistent — Recent feeds reporting a “significant increase” actually show zero shares, so no clear short‑squeeze dynamics are evident from the available data. (internal short‑interest entries)
• Negative Sentiment: Insider selling — Senior insider Priya Singhal sold 2,660 shares (~$531k), which some investors interpret as a modest negative signal about near‑term insider conviction. Insider Form 4
• Negative Sentiment: Legacy franchise pressure and execution risks — Analysts caution that MS franchise erosion and the challenges of scaling Leqembi access/commercialization could limit upside and add execution risk. Franchise Pressure Analysis

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.